Delin Ventures is proud to see the collaboration announced this week between IMMvention Therapeutix, Inc. one of our portfolio companies, and Novo Nordisk, to develop IMMvention’s first-in-class BACH1 inhibitors to treat sickle cell disease. Exciting news and a great partner to bring these treatments forward into the clinic and beyond. Congrats Anil Goyal, Don Haut, PhD (he/him) and the IMMvention team!
We’re excited to announce a transformative collaboration with Novo Nordisk. Together, we’re working towards the advancement of accessible, effective oral therapies for sickle cell disease and other chronic conditions, addressing critical unmet needs worldwide. This partnership is a pivotal step in our mission to improve global health, and we’re grateful to our team, advisors, and investors for making this milestone possible. Read more about this exciting development in our press release: https://lnkd.in/ebYC_Ab7 #Collaboration #Innovation #Healthcare #SickleCellDisease #BACH1Inhibitors #NovoNordisk #IMMvention #UNC #RTP #DURHAM #RAREDISEASE #NCBIOTECH